{"result": "(\"entity\"<|>BRUTTOMESSO D<|>PERSON<|>Bruttomesso D is an author of a study on blood glucose variability in Type 1 diabetic patients.)\n##\n(\"entity\"<|>CRAZZOLARA D<|>PERSON<|>Crazzolara D is an author of a study on blood glucose variability in Type 1 diabetic patients.)\n##\n(\"entity\"<|>MARAN A<|>PERSON<|>Maran A is an author of a study on blood glucose variability in Type 1 diabetic patients.)\n##\n(\"entity\"<|>COSTA S<|>PERSON<|>Costa S is an author of a study on blood glucose variability in Type 1 diabetic patients.)\n##\n(\"entity\"<|>DAL POS M<|>PERSON<|>Dal Pos M is an author of a study on blood glucose variability in Type 1 diabetic patients.)\n##\n(\"entity\"<|>GIRELLI A<|>PERSON<|>Girelli A is an author of a study on blood glucose variability in Type 1 diabetic patients.)\n##\n(\"entity\"<|>DIABET MED<|>ORGANIZATION<|>Diabet Med is a medical journal that published studies related to diabetes management.)\n##\n(\"entity\"<|>PALA L<|>PERSON<|>Pala L is an author of a meta-analysis on insulin infusion vs multiple injection regimens in type 1 diabetes.)\n##\n(\"entity\"<|>DICEMBRINI I<|>PERSON<|>Dicembrini I is an author of a meta-analysis on insulin infusion vs multiple injection regimens in type 1 diabetes.)\n##\n(\"entity\"<|>MANNUCCI E<|>PERSON<|>Mannucci E is an author of a meta-analysis on insulin infusion vs multiple injection regimens in type 1 diabetes.)\n##\n(\"entity\"<|>PICKUP JC<|>PERSON<|>Pickup JC is an author of a meta-analysis on severe hypoglycaemia and glycaemic control in Type 1 diabetes.)\n##\n(\"entity\"<|>SUTTON AJ<|>PERSON<|>Sutton AJ is an author of a meta-analysis on severe hypoglycaemia and glycaemic control in Type 1 diabetes.)\n##\n(\"entity\"<|>ACTA DIABETOLOGICA<|>ORGANIZATION<|>Acta Diabetol is a medical journal that published studies related to diabetes management.)\n##\n(\"entity\"<|>INSULINA<|>EVENT<|>Insulin is a hormone used in the treatment of diabetes, particularly in managing blood glucose levels.)\n##\n(\"entity\"<|>DIABETES TIPO 2<|>EVENT<|>Diabetes Tipo 2 is a chronic condition that affects the way the body processes blood sugar (glucose).)\n##\n(\"relationship\"<|>BRUTTOMESSO D<|>DIABET MED<|>Bruttomesso D authored a study published in Diabet Med<|>7)\n##\n(\"relationship\"<|>CRAZZOLARA D<|>DIABET MED<|>Crazzolara D authored a study published in Diabet Med<|>7)\n##\n(\"relationship\"<|>MARAN A<|>DIABET MED<|>Maran A authored a study published in Diabet Med<|>7)\n##\n(\"relationship\"<|>COSTA S<|>DIABET MED<|>Costa S authored a study published in Diabet Med<|>7)\n##\n(\"relationship\"<|>DAL POS M<|>DIABET MED<|>Dal Pos M authored a study published in Diabet Med<|>7)\n##\n(\"relationship\"<|>GIRELLI A<|>DIABET MED<|>Girelli A authored a study published in Diabet Med<|>7)\n##\n(\"relationship\"<|>PALA L<|>ACTA DIABETOLOGICA<|>Pala L authored a meta-analysis published in Acta Diabetol<|>7)\n##\n(\"relationship\"<|>DICEMBRINI I<|>ACTA DIABETOLOGICA<|>Dicembrini I authored a meta-analysis published in Acta Diabetol<|>7)\n##\n(\"relationship\"<|>MANNUCCI E<|>ACTA DIABETOLOGICA<|>Mannucci E authored a meta-analysis published in Acta Diabetol<|>7)\n##\n(\"relationship\"<|>PICKUP JC<|>DIABET MED<|>Pickup JC authored a meta-analysis published in Diabet Med<|>7)\n##\n(\"relationship\"<|>SUTTON AJ<|>DIABET MED<|>Sutton AJ authored a meta-analysis published in Diabet Med<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en\n                                                                       control metabólico y más riesgo de hipoglucemias                                  el paciente con enfermedad renal crónica. Med Clin (Barc). 2014;142(2):85.e1-10.\n                                                                       graves\n           Menor incidencia de hipoglucemias no graves                 Hipoglucemias de menor gravedad disminuyen hasta\n                                                                       un 75% con ISCI frente a las DMI                                            71  Respecto        a la introducción de fármacos                   tras el parto en mujeres con DM2\n           Menor variabilidad glucémica                                                                                                                e  hipertensión arterial, señale la respuesta incorrecta:\n           Adaptabilidad del ritmo basal y de los bolos de                                                                                             A.  Los IECA son compatibles con la lactancia.\n           insulina según las necesidades\n           Empleo de la misma zona de punción para la                                                                                                  B.  Los ARA-II son compatibles con la lactancia.\n           administración de la insulina, con lo que se                                                                                                C.  La repaglinida es compatible con la lactancia.\n           reduce la variabilidad en la absorción                                                                                                      D.  La glibenclamida es compatible con la lactancia.\n           Menor riesgo de hipoglucemias nocturnas y de\n           hiperglucemias de ayuno (fenómeno del alba)\n           Mejoría de la calidad de vida percibida                                                                                                     COMENTARIO\n         Referencias:                                                                                                                                  En vista de los beneficios nutricionales                  e inmunológicos inmediatos de la                  lactancia mater-\n         •  Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, et al. In Type 1 diabetic patients with good glycaemic control,       na para el bebé, todas las mujeres, incluidas las que tienen diabetes, deben recibir apoyo\n            blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin      en sus intentos         de   amamantar. La lactancia               materna también            puede conferir         beneficios\n            glargine. Diabet Med. 2008;25(3):326-32.                                                                                                   metabólicos a largo plazo tanto para la madre como para la descendencia.\n         •  Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes:\n            an updated meta-analysis of randomized clinical trials. Acta Diabetol. 2019 Apr 3. [Epub ahead of print].\n         •  Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin               El enalapril (IECA) se excreta en la leche materna en cantidad clínicamente no                                    significativa\n            injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765-74.                                          y no se han observado problemas en lactantes cuyas madres la tomaban, ni problemas\n                                                                                                                                                       en el establecimiento de la lactancia. Es una medicación de uso autorizado en lactantes\n         ¿Cuál de las siguientes situaciones no es causa de un aumento de los                                                                          pequeños y, fuera de ficha técnica, en neonatos.\n     70                                                                                                                                                Los ARA-II, al menos candesartán, eprosartán, valsartán, losartán y olmesartán tienen ries-\n         requerimientos de insulina en un paciente diabético?                                                                                          go bajo probable, es decir son bastante seguros.\n         A.   Infección urinaria.                                                                                                                      La repaglinida presenta riesgo potencial de hipoglucemia y se han observado efectos ad-\n         B.   Encamamiento por fractura.                                                                                                               versos     en   animales      lactantes. Se clasifica, por tanto, como riesgo                       alto   probable      para    la\n         C.   Insuficiencia renal.                                                                                                                     lactancia, poco seguro.\n         D.   Todas.                                                                                                                                   Los datos farmacocinéticos                de las sulfonilureas (peso            molecular moderadamente elevado\n                                                                                                                                                       y muy     alto porcentaje de fijación a proteínas plasmáticas)                        explican el nulo o ínfimo paso a\n         COMENTARIO                                                                                                                                    la leche observado. Aunque los niveles de glucemia fueron normales en un lactante cuya\n         Las    enfermedades concomitantes                   (infecciones, cirugía, hospitalización)               aumentan        las ne-             madre tomaba glibencamida, algún autor sugiere vigilar síntomas de hipoglucemia en el\n         cesidades de insulina en los sujetos con diabetes, tanto por el estrés propio de la situación                                                 lactante. Por tanto queda clasificado como: riesgo muy bajo para la lactancia, compatible.\n         como por la situación de reposo.                                                                                                              Referencias:\n                                                                                                                                                       • http://e-lactancia.org (acceso 12 de marzo de 2019).\n         Sin embargo, en la insuficiencia renal, el aclaramiento de la insulina disminuye, lo que                                        re-           • Management of Diabetes in\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}